Provides a comprehensive yet concise resource
Provides a guide for the clinician facing cardiovascular toxicity in cancer and hematologic patients

Written by experts in the field

Provides a comprehensive yet concise resource. Provides a guide for the clinician facing cardiovascular toxicity in cancer and hematologic patients. Written by experts in the field.

Autorentext
Antonio Russo, MD, PhD
Full Professor of Medical Oncology
Department of Surgical, Oncological and Oral Sciences (Di.Chir.On.S.)
University of Palermo, Italy
Director of Medical Oncology Section, University Hospital P. Giaccone
Palermo, Italy
Giuseppina Novo, MD, PhD
Associate Professor of Cardiology
Biomedic Department of Internal Medicine and Specialities (DIBIMIS) University of Palermo, Italy
Division of Cardiology, University Hospital P. Giaccone
Palermo, Italy
Patrizio Lancellotti, MD, PhD
University of Liège Hospital, GIGA Cardiovascular Sciences
Department of Cardiology
CHU Sart Tilman, Liège, Belgium
Gruppo Villa Maria Care and Research, Anthea Hospital
Bari, Italy
Antonio Giordano, MD PhD
Director, Sbarro Institute for Cancer Research and Molecular Medicine and Center of Biotechnology
College of Science and Technology
Temple University
PA 19122
USA
Fausto J. Pinto, MD, PhD, FESC, FACC, FSCAI, FASE
Professor, University Hospital Santa Maria, CHLN
University of Lisbon, Portugal
Dept. of Cardiology
Av Prof Egas Moniz
Lisboa 1649-028 Portugal

Klappentext
Provides a comprehensive yet concise resource Provides a guide for the clinician facing cardiovascular toxicity in cancer and hematologic patients Written by experts in the field

Zusammenfassung
Provides a comprehensive yet concise resource
Provides a guide for the clinician facing cardiovascular toxicity in cancer and hematologic patients

Written by experts in the field

Inhalt
Introduction.- Mechanisms of Cardiovascular Damage Induced by Traditional Chemotherapy.- Molecular Mechanisms of Cardiovascular Damage Induced by Anti HER2 Therapies.- Cardiovascular Damage Induced by Radiotherapy.- Cardiovascular Damage Induced by Anti-VEGF Therapy.- Cardiovascular Damage Induced by Anti-BCR-ABL TKIs.- Heart Failure and Left Ventricular Dysfunction.- Coronary Artery Disease.- Peripheral Artery Disease and Stroke.- Valvular Heart Disease.- Arterial Hypertension.- Atrial Fibrillation in Cancer.- Management of QT Prolongation Induced by Anti-cancer Drugs.- Pulmonary Hypertension Induced by Anti-cancer Drugs.- Venous Thromboembolism.- Early Detection of Cardiac Damage.- Diagnosis of Cardiac Damage: Role of Stress Echo.- Early Detection and Monitoring of Vascular Damage.- Prevention and Clinical Management of Cardiovascular Damage Induced by Anticancer Drugs: Need for Early Biomarkers and Cardio- and Vasculo-Protection in Personalized Therapy.- Cardiovascular Damage in Clinical Trials.